Ariad Pharmaceuticals Inc fka ARIA

[BTH]

Excerpt from Merck's February, 2011 10-K

MK-8669, ridaforolimus, is a novel mTOR (mammalian target of rapamycin) inhibitor being evaluated
for the treatment of cancer. Merck is currently developing ridaforolimus in multiple cancer indications under an
exclusive license and collaboration agreement with ARIAD Pharmaceuticals, Inc. (“ARIAD”). In January 2011,
ARIAD announced top-line data showing that ridaforolimus met the primary endpoint of improved progression-
free survival compared to placebo in the Phase III SUCCEED trial conducted in patients with metastatic soft tissue
or bone sarcomas who previously had a favorable response to chemotherapy. Complete findings from the
SUCCEED trial will be submitted for presentation at an upcoming medical meeting in 2011. This trial remains
active, and study participants continue to be followed to gather additional data on secondary endpoints, including
overall survival and the safety profile of ridaforolimus. Merck currently plans to file an NDA with the FDA for oral
ridaforolimus in 2011, subject to final collection and analysis of all available data from the trial.